Biohaven Ltd. is garnering increased attention from analysts due to significant advancements in its drug pipeline and strategic positioning as key milestones approach in 2025. The company's progress, particularly with troriluzole for spinocerebellar ataxia (SCA) and BHV-1300, an IgG-modulating therapy, has fueled optimism.
Troriluzole's Potential in Spinocerebellar Ataxia
The resubmission of the New Drug Application (NDA) for troriluzole for the SCA indication is a critical development. This NDA is supported by new study data, giving it a 60% probability of approval. If approved, troriluzole could achieve peak sales exceeding $1 billion, addressing a significant unmet need in SCA treatment.
BHV-1300: A Novel IgG Degrader
Biohaven's degrader program, highlighted by BHV-1300, is showing considerable promise. Interim updates from the Phase 1 trial indicate strong IgG reduction with a new dosing format. Studies have demonstrated substantial reductions in targeted IgG levels, achieving over 60% reduction even at the lowest dose tested. This suggests a refined and potentially superior therapeutic approach for IgG-related disorders.
Advancing BHV-7000 for Epilepsy and Bipolar Disorder
BHV-7000, a Kv7 activator, is another key asset in Biohaven's pipeline. The company has completed enrollment for a pivotal Phase 2/3 trial of BHV-7000 for bipolar disorder, signaling positive momentum in its neuropsychiatric program. Its advancement in epilepsy also contributes to the company’s diversified portfolio.
Analyst Confidence and Market Outlook
Jason Gerberry, an analyst at Bank of America Securities, has reiterated a 'Buy' rating on Biohaven (BHVN) stock. This positive outlook is based on the company's pipeline advancements and the favorable risk-reward profile as Biohaven approaches key milestones in 2025. Similarly, Morgan Stanley analyst Terence Flynn also maintained a 'Buy' rating with a price target of $69.00, emphasizing the potential of BHV-1300 and the overall breadth of Biohaven's pipeline.
Flynn suggests that any market weakness could present an investment opportunity, given the company’s robust pipeline and strategic direction. Bernstein also maintained a 'Buy' rating on the stock with a $63.00 price target.
